<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31642482</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>21</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>Neuronal over-expression of Oxr1 is protective against ALS-associated mutant TDP-43 mislocalisation in motor neurons and neuromuscular defects in vivo.</ArticleTitle><Pagination><StartPage>3584</StartPage><EndPage>3599</EndPage><MedlinePgn>3584-3599</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddz190</ELocationID><Abstract><AbstractText>A common pathological hallmark of amyotrophic lateral sclerosis (ALS) and the related neurodegenerative disorder frontotemporal dementia, is the cellular mislocalization of transactive response DNA-binding protein 43&#xa0;kDa (TDP-43). Additionally, multiple mutations in the TARDBP gene (encoding TDP-43) are associated with familial forms of ALS. While the exact role for TDP-43 in the onset and progression of ALS remains unclear, the identification of factors that can prevent aberrant TDP-43 localization and function could be clinically beneficial. Previously, we discovered that the oxidation resistance 1 (Oxr1) protein could alleviate cellular mislocalization phenotypes associated with TDP-43 mutations, and that over-expression of Oxr1 was able to delay neuromuscular abnormalities in the hSOD1G93A ALS mouse model. Here, to determine whether Oxr1 can protect against TDP-43-associated phenotypes in vitro and in vivo, we used the same genetic approach in a newly described transgenic mouse expressing the human TDP-43 locus harbouring an ALS disease mutation (TDP-43M337V). We show in primary motor neurons from TDP-43M337V mice that genetically-driven Oxr1 over-expression significantly alleviates cytoplasmic mislocalization of mutant TDP-43. We also further quantified newly-identified, late-onset neuromuscular phenotypes of this mutant line, and demonstrate that neuronal Oxr1 over-expression causes a significant reduction in muscle denervation and neuromuscular junction degeneration in homozygous mutants in parallel with improved motor function and a reduction in neuroinflammation. Together these data support the application of Oxr1 as a viable and safe modifier of TDP-43-associated ALS phenotypes.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Matthew G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford OX1 3PT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finelli</LastName><ForeName>Matt&#xe9;a J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford OX1 3PT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sleigh</LastName><ForeName>James N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, Institute of Neurology, University College London, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddington</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford OX1 3PT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Kay E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford OX1 3PT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliver</LastName><ForeName>Peter L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Department of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford OX1 3PT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Harwell Institute, Harwell Campus, Didcot, Oxfordshire, OX11 0RD, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_EX_MR/P502005/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S006990/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TALBOT-GORDON/APR15/831-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C419777">OXR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009121" MajorTopicYN="N">Muscle Denervation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009132" MajorTopicYN="N">Muscles</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31642482</ArticleId><ArticleId IdType="pmc">PMC6927465</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddz190</ArticleId><ArticleId IdType="pii">5559948</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talbot K., Feneberg E., Scaber J., Thompson A.G. and Turner M.R. (2018) Amyotrophic lateral sclerosis: the complex path to precision medicine. J. Neurol., 265, 2454&#x2013;2462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6182683</ArticleId><ArticleId IdType="pubmed">30054789</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M. et al. (2006) Ubiquitinated TDP-43 in Frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314, 130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Al-Chalabi A., Chio A., Hardiman O., Kiernan M.C., Rohrer J.D., Rowe J., Seeley W. and Talbot K. (2017) Genetic screening in sporadic ALS and FTD. J Neurol Neurosurg Psychiatry., 88, 1042&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5740553</ArticleId><ArticleId IdType="pubmed">28642287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong L.K., Uryu K., Trojanowski J.Q. and Lee V.M.Y. (2008) TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neuro Signals., 16, 41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">18097159</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrado L., Ratti A., Gellera C., Buratti E., Castellotti B., Carlomagno Y., Ticozzi N., Mazzini L., Testa L., Taroni F. et al. (2009) High frequency of TARDBP gene mutations in italian patients with amyotrophic lateral sclerosis. Hum. Mutat., 30, 688&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">19224587</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoud H., Valdmanis P.N., Kabashi E., Dion P., Dupr&#xe9; N., Camu W., Meininger V. and Rouleau G.A. (2009) Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. J. Med. Genet., 46, 112&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">18931000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., Mcconkey B.J., Velde C.V., Bouchard J.-P., Lacomblez L., Pochigaeva K. et al. (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet., 40, 572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Blair I.P., Tripathi V.B., Xun H., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L. et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Sci. Reports, 319, 1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O., Powell J.F., Andersen P.M. and Al-Chalabi A. (2012) ALSoD: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum. Mutat., 33, 1345&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">22753137</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. (2015) Functional significance of TDP-43 mutations in disease. Adv. Genet., 91, 1&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiesel F.C. and Kahle P.J. (2011) TDP-43 and FUS/TLS: cellular functions and implications for neurodegeneration. FEBS J., 278, 3550&#x2013;3568.</Citation><ArticleIdList><ArticleId IdType="pubmed">21777389</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Polymenidou M. and Cleveland D.W. (2010) TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet., 19, R46&#x2013;R64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C., Zennaro E., Fallini C., Weber M., Sommacal A., Buratti E., Silani V. and Ratti A. (2009) TDP-43 is recruited to stress granules in conditions of oxidative insult. J. Neurochem., 111, 1051&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey C.M., Cenik B., Sephton C.F., Dries D.R., Mayer P., Good S.K., Johnson B.A., Herz J. and Yu G. (2011) TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Mol. Cell. Biol., 31, 1098&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067820</ArticleId><ArticleId IdType="pubmed">21173160</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald K.K., Aulas A., Destroismaisons L., Pickles S., Beleac E., Camu W., Rouleau G.A. and Velde C.V. (2011) TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum. Mol. Genet., 20, 1400&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">21257637</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutihac R., Alegre-Abarrategui J., Gordon D., Farrimond L., Yamasaki-Mann M., Talbot K. and Wade-Martins R. (2015) TARDBP pathogenic mutations increase cytoplasmic translocation of TDP-43 and cause reduction of endoplasmic reticulum Ca2+ signaling in motor neurons. Neurobiol. Dis., 75, 64&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">25526708</ArticleId></ArticleIdList></Reference><Reference><Citation>Finelli M.J., Sanchez-Pulido L., Liu K.X., Davies K.E. and Oliver P.L. (2016) The evolutionarily conserved Tre2/Bub2/Cdc16 (TBC), lysin motif (LysM), domain catalytic (TLDc) domain is neuroprotective against oxidative stress. J. Biol. Chem., 291, 2751&#x2013;2763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4742741</ArticleId><ArticleId IdType="pubmed">26668325</ArticleId></ArticleIdList></Reference><Reference><Citation>Finelli M.J. and Oliver P.L. (2017) TLDc proteins: new players in the oxidative stress response and neurological disease. Mamm. Genome., 28, 395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5614904</ArticleId><ArticleId IdType="pubmed">28707022</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkert M.R., Elliott N.A. and Housman D.E. (2000) Functional genomics reveals a family of eukaryotic oxidation protection genes. PNAS, 97, 14530&#x2013;14535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18953</ArticleId><ArticleId IdType="pubmed">11114193</ArticleId></ArticleIdList></Reference><Reference><Citation>Finelli M.J., Liu K.X., Wu Y., Oliver P.L. and Davies K.E. (2015) Oxr1 improves pathogenic cellular features of ALS-associated FUS and TDP-43 mutations. Hum Mol Genet., 24, 3529&#x2013;3544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4498158</ArticleId><ArticleId IdType="pubmed">25792726</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K.X., Edwards B., Lee S., Finelli M.J., Davies B., Davies K.E. and Oliver P.L. (2015) Neuron-specific antioxidant OXR1 extends survival of a mouse model of amyotrophic lateral sclerosis. Brain, 138, 1167&#x2013;1181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407188</ArticleId><ArticleId IdType="pubmed">25753484</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Alton S., Altshuler M., Cannon A., Dickson D.W., Petrucelli L. and Lewis J. (2014) Divergent phenotypes in mutant TDP-43 transgenic mice highlight potential confounds in TDP-43 transgenic modeling. PLoS One, 9, e86513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899264</ArticleId><ArticleId IdType="pubmed">24466128</ArticleId></ArticleIdList></Reference><Reference><Citation>McGoldrick P., Joyce P.I., Fisher E.M.C. and Greensmith L. (2013) Rodent models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta, 1832, 1421&#x2013;1436.</Citation><ArticleIdList><ArticleId IdType="pubmed">23524377</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T. and Rothstein J.D. (2015) Rodent models of amyotrophic lateral sclerosis. Curr. Protoc. Pharmacol., 69, 5.67.1&#x2013;5.67.21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan X., Chiang P.-M., Price D.L. and Wong P.C. (2010) Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. PNAS, 107, 16325&#x2013;16330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941282</ArticleId><ArticleId IdType="pubmed">20736350</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings N.R., Puttaparthi K., Luther C.M., Burns D.K. and Elliott J.L. (2010) Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis., 40, 404&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">20621187</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai K.-J., Yang C.-H., Fang Y.-H., Cho K.-H., Chien W.-L., Wang W.-T., Wu T.-W., Lin C.-P., Fu W.-M. and Shen C.-K.J. (2010) Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J. Exp. Med., 207, 1661&#x2013;1673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2916125</ArticleId><ArticleId IdType="pubmed">20660618</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I., Bell S., Cairns N.J., Miller T.M. and Baloh R.H. (2009) TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. PNAS, 106, 18809&#x2013;18814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H., Kleinberger G., Janssens J., Pereson S., Joris G., Cuijt I., Smits V., Ceuterick-de Groote C., Van Broeckhoven C. and Kumar-Singh S. (2010) TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. PNAS, 107, 3858&#x2013;3863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.-F., Gendron T.F., Zhang Y.-J., Lin W.-L., D&#x2019;Alton S., Sheng H., Casey M.C., Tong J., Knight J. et al. (2010) Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci., 30, 10851&#x2013;10859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.-F., Zhang Y.-J., Lin W.-L., Cao X., Stetler C., Dickson D.W., Lewis J. and Petrucelli L. (2011) Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol. Neurodegener., 6, 73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216869</ArticleId><ArticleId IdType="pubmed">22029574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Arakawa H., Wang L., Okolo O., Siedlak S.L., Jiang Y., Gao J., Xie F., Petersen R.B. and Wang X. (2017) Motor-coordinative and cognitive dysfunction caused by mutant TDP-43 could be reversed by inhibiting its mitochondrial localization. Mol Ther., 25, 127&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363201</ArticleId><ArticleId IdType="pubmed">28129109</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D., Dafinca R., Scaber J., Alegre-Abarrategui J., Farrimond L., Scott C., Biggs D., Kent L., Oliver P.L., Davies B. et al. (2018) Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction. Neurobiol. Dis., 121, 148&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">30290270</ArticleId></ArticleIdList></Reference><Reference><Citation>Carriedo S.G., Yin H.Z. and Weiss J.H. (1996) Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J. Neurosci., 16, 4069&#x2013;4079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578994</ArticleId><ArticleId IdType="pubmed">8753869</ArticleId></ArticleIdList></Reference><Reference><Citation>McFadyen M.P., Kusek G., Bolivar V.J. and Flaherty L. (2003) Differences among eight inbred strains of mice in motor ability and motor learning on a rotorod. Genes Brain Behav., 2, 214&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">12953787</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello V. and Francolini M. (2017) Neuromuscular junction dismantling in amyotrophic lateral sclerosis. Int. J. Mol. Sci., 18, E2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666774</ArticleId><ArticleId IdType="pubmed">28972545</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A. and Glass J.D. (2004) Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol., 185, 232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney E.B., de Winter F. and Verhaagen J. (2014) ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front. Neurosci., 8, 252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4132373</ArticleId><ArticleId IdType="pubmed">25177267</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Tong J., Bi F., Zhou H. and Xia X.G. (2012) Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J. Clin. Invest., 122, 107&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248298</ArticleId><ArticleId IdType="pubmed">22156203</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H., Huang C., Chen H., Wang D., Landel C.P., Xia P.Y., Bowser R., Liu Y.J. and Xia X.G. (2010) Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet., 6, e1000887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845661</ArticleId><ArticleId IdType="pubmed">20361056</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh J.N., Burgess R.W., Gillingwater T.H. and Cader M.Z. (2014) Morphological analysis of neuromuscular junction development and degeneration in rodent lumbrical muscles. J. Neurosci. Methods, 227, 159&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4120659</ArticleId><ArticleId IdType="pubmed">24530702</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R. and Zoing M.C. (2011) Amyotrophic lateral sclerosis. Lancet, 377, 942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey D., Schneider C., Xu L., Borg J., Spooren W. and Caroni P. (2000) Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J. Neurosci., 20, 2534&#x2013;2542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772256</ArticleId><ArticleId IdType="pubmed">10729333</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegedus J., Putman C.T. and Gordon T. (2007) Time course of preferential motor unit loss in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis., 28, 154&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">17766128</ArticleId></ArticleIdList></Reference><Reference><Citation>Augusto V., Padovani C.R. and Campos G.E.R. (2004) Skeletal muscle fiber types in C57BL6J mice. Brazilian J. Morphol. Sci., 21, 89&#x2013;94.</Citation></Reference><Reference><Citation>Jensen L., J&#xf8;rgensen L.H., Bech R.D., Frandsen U. and Schr&#xf8;der H.D. (2016) Skeletal muscle remodelling as a function of disease progression in amyotrophic lateral sclerosis. Biomed Res Int., 2016, 5930621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4852332</ArticleId><ArticleId IdType="pubmed">27195289</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai R.J., Vukovic J., Dunlop S., Grounds M.D. and Shavlakadze T. (2011) Striking denervation of neuromuscular junctions without lumbar motoneuron loss in geriatric mouse muscle. PLoS One., 6, e28090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229526</ArticleId><ArticleId IdType="pubmed">22164231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebstein S.Y., Yagudayeva I. and Shneider N.A. (2019) Mutant TDP-43 causes early-stage dose-dependent motor neuron degeneration in a TARDBP Knockin mouse model of ALS. Cell Rep., 26, 364&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">30625319</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy D., Kato T. and Kushner P.D. (1994) Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J. Neurosci. Res., 38, 336&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">7523689</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Cagnin A., Turkheimer F.E., Miller C.C.J., Shaw C.E., Brooks D.J., Leigh P.N. and Banati R.B. (2004) Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis., 15, 601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Alrafiah A.R. (2018) From mouse models to human disease: an approach for amyotrophic lateral sclerosis. In Vivo, 32, 983&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199613</ArticleId><ArticleId IdType="pubmed">30150420</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford N.J., Zhang Y.-J., Baker M., Gass J.M., Finch N.A., Xu Y.-F., Stewart H., Kelley B.J., Kuntz K., Crook R.J.P. et al. (2008) Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet, 4, e1000193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527686</ArticleId><ArticleId IdType="pubmed">18802454</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J., Wils H., Kleinberger G., Joris G., Cuijt I., Ceuterick-De Groote C., Van Broeckhoven C. and Kumar-Singh S. (2013) Over-expression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol. Neurobiol., 48, 22&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3718993</ArticleId><ArticleId IdType="pubmed">23475610</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott N.A. and Volkert M.R. (2004) Stress induction and mitochondrial localization of Oxr1 proteins in yeast and humans. Mol. Cell. Biol., 24, 3180&#x2013;3187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC381681</ArticleId><ArticleId IdType="pubmed">15060142</ArticleId></ArticleIdList></Reference><Reference><Citation>Svistunova D.M., Simon J.N., Rembeza E., Crabtree M., Yue W.W., Oliver P.L. and Finelli M.J. (2018) Oxidation resistance 1 regulates post-translational modifications of peroxiredoxin 2 in the cerebellum. Free Radic. Biol. Med., 130, 151&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6339520</ArticleId><ArticleId IdType="pubmed">30389497</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M., Luna L., S&#xf8;rb&#xf8; J.G., Alseth I., Johansen R.F., Backe P.H., Danbolt N.C., Eide L. and Bj&#xf8;r&#xe5;s M. (2014) Human OXR1 maintains mitochondrial DNA integrity and counteracts hydrogen peroxide-induced oxidative stress by regulating antioxidant pathways involving p21. Free Radic. Biol. Med., 77, 41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">25236744</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollari E., Goldsteins G., Bart G., Koistinaho J. and Giniatullin R. (2014) The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Front. Cell. Neurosci., 8, 131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026683</ArticleId><ArticleId IdType="pubmed">24860432</ArticleId></ArticleIdList></Reference><Reference><Citation>Finelli M.J., Paramo T., Pires E., Ryan B.J., Wade-Martins R., Biggin P.C., McCullagh J. and Oliver P.L. (2019) Oxidation resistance 1 modulates glycolytic pathways in the cerebellum via an interaction with Glucose-6-phosphate Isomerase. Mol Neurobiol., 56, 1558&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6368252</ArticleId><ArticleId IdType="pubmed">29905912</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzano S., Checconi P., Hanschmann E.M., Lillig C.H., Bowler L.D., Chan P., Vaudry D., Mengozzi M., Coppo L., Sacre S. et al. (2014) Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal. Proc Natl Acad Sci U S A., 111, 12157&#x2013;12162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4143057</ArticleId><ArticleId IdType="pubmed">25097261</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto I., Staub A., Benoist C. and Mathis D. (1999) Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science, 286, 1732&#x2013;1735.</Citation><ArticleIdList><ArticleId IdType="pubmed">10576739</ArticleId></ArticleIdList></Reference><Reference><Citation>Solleiro-Villavicencio H. and Rivas-Arancibia S. (2018) Effect of chronic oxidative stress on neuroinflammatory response mediated by CD4+T cells in neurodegenerative diseases. Front Cell Neurosci., 12, 114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5934485</ArticleId><ArticleId IdType="pubmed">29755324</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachiller S., Jim&#xe9;nez-Ferrer I., Paulus A., Yang Y., Swanberg M., Deierborg T. and Boza-Serrano A. (2018) Microglia in neurological diseases: a road map to brain-disease dependent-inflammatory response. Front Cell Neurosci., 12, 488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6305407</ArticleId><ArticleId IdType="pubmed">30618635</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow S.A. and Barres B.A. (2017) Reactive astrocytes: production, function, and therapeutic potential. Immunity 2017, 46, 957&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">28636962</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer G.J. and Torricelli J.R. (2007) Isolation and culture of adult neurons and neurospheres. Nat. Protoc., 2, 1490&#x2013;1498.</Citation><ArticleIdList><ArticleId IdType="pubmed">17545985</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S., Bogaert E., Van Damme P. and Van Den Bosch L. (2016) Inside out: the role of nucleocytoplasmic transport in ALS and FTLD. Acta Neuropathol., 132, 159&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947127</ArticleId><ArticleId IdType="pubmed">27271576</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura A.L., Upunski V., Troakes C., Kathe C., Fratta P., Howell M., Gallo J.M., Hortob&#xe1;gyi T., Shaw C.E. and Rogelj B. (2010) Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain, 133, 1763&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward M.E., Taubes A., Chen R., Miller B.L., Sephton C.F., Gelfand J.M., Minami S., Boscardin J., Martens L.H., Seeley W.W. et al. (2014) Early retinal neurodegeneration and impaired ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. J. Exp. Med., 211, 1937&#x2013;1945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172214</ArticleId><ArticleId IdType="pubmed">25155018</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker L.A., Huang B., Bieri G., Ma R., Knowles D.A., Jafar-Nejad P., Messing J., Kim H.J., Soriano A., Auburger G. et al. (2017) Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature, 544, 367&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner B.J., Parkinson N.J., Davies K.E. and Talbot K. (2009) Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model. Neurobiol. Dis., 34, 511&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">19332122</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt D.R., Davis J., Fischer M., Lee M.K., Slunt H.H., Ratovitsky T., Regard J., Copeland N.G., Jenkins N.A., Sisodia S.S. and Price D.L. (1996) A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet. Anal., 13, 159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">9117892</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver P.L., Finelli M.J., Edwards B., Bitoun E., Butts D.L., Becker E.B.E., Cheeseman M.T., Davies B. and Davies K.E. (2011) Oxr1 is essential for protection against oxidative stress-induced neurodegeneration. PLoS Genet., 7, e1002338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197693</ArticleId><ArticleId IdType="pubmed">22028674</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh J.N., Grice S.J., Burgess R.W., Talbot K. and Cader M.Z. (2014) Neuromuscular junction maturation defects precede impaired lower motor neuron connectivity in Charcot-Marie-tooth type 2D mice. Hum. Mol. Genet. 23: 39&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990164</ArticleId><ArticleId IdType="pubmed">24368416</ArticleId></ArticleIdList></Reference><Reference><Citation>Boston University Research  https://www.bu.edu/researchsupport/compliance/animal-care/working-with-animals/research/sample-size-calculations-iacuc/ Support sample size calculation.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>